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Background: The rapid growth of prescription drug expenditures is a major problem in South Korea. Accordingly,
the South Korean government introduced a positive listing system in 2006. They also adopted various price
reduction policies. Nevertheless, the total expenditure for lipid-lowering drugs have steadily increased throughout
South Korea. The present study explores the factors that have influenced the increased expenditures of lipid-lowering
drugs with a particular focus on the effects of statins in this process.
Methods: This paper investigates the National Health Insurance claims data for prescribed lipid-lowering drugs
collected between January 1, 2005 and December 31, 2009. We specifically focused on statins and assessed the yearly
variation of statin expenditure by calculating the increased rate of paired pharmaceutical expenditures over a 2 year
period. Our study classified statins into three categories: new entrants, core medicines and exiting medicines. For core
medicines, we further examined influencing factors such as price, amount of drugs consumed by volume, and
prescription changes (substitutes for other drug).
Results: Statin expenditure showed an average annual increase of 25.7% between 2005 and 2009. Among the different
statins, the expenditure of atorvastatin showed a 36.6% annual increase rate, which was the most dramatic among all
statins. Also we divided expenditure for core medicines by the price factor, volume factor, and prescription change. The
result showed that annual weighted average prices of individual drug decreased each year, which clearly showed that
price influenced statin expenditure in a negative direction. The use of generic drugs containing the same active
ingredient as name-brand drugs increased and negatively affected statin expenditure (Generic Mix effect). However, the
use of relatively expensive ingredients within statin increase, Ingredient Mix effect contributed to increased statin
expenditure (Ingredient Mix effect). In particular, the volume effect was found to be critical for increasing statin
expenditure as the amount of statin consumed increased steadily throughout the study period.
Conclusions: The recent rapid increase in statin expenditure can largely be attributed to an increase in consumption
volume. In order to check drug expenditures effectively in our current situation, in which chronic diseases remain steadily
on the rise, it is necessary to not only have supply-side initiatives such as price reduction, but also demand-side
initiatives that could control drug consumption volume, for example: educational programs for rational prescription,
generic drug promotional policies, and policies providing prescription targets.* Correspondence: smjang@gachon.ac.kr
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In Korea, the National Health Insurance prescription drug
expenditure has increased about 13.2% annually for the
past decade (2001–2010) [1]. This cost makes it a major
threat to the sustainability of Korea's National Health In-
surance program. Accordingly, the Korean government
has introduced various policies to check these costs that
have continued to grow since 2006. In December 2006,
they introduced the positive listing system, inducing
pharmaceutical companies to consider cost-effectiveness
as one of their major concerns [2], and required them to
cut the price of original drugs by 20% when their patents
expire. Also, from 2007 to 2010, they re-evaluated the
cost-effectiveness of already listed drugs and lowered the
cost of drugs with low cost-effectiveness or delisted them
[3]. This re-evaluation of listed drugs was done mainly to
drugs for chronic diseases like hyperlipidemia and hyper-
tension. In 2009, pharmaceutical companies also intro-
duced the price-volume agreement system.
If we divide factors for prescription drug expenditure
into two categories – the price factor and the volume
factor – most pharmaceutical regulations introduced in
Korea between 2006 and 2009 utilized supply-side initia-
tives like the price and the drug-listing decision method
[4]. As a result, the government rarely applied demand-
side initiatives, which efficiently control prescription
drug expenditures by checking their volume on the stage
of drug prescription and usage. In this case, if the main
reason for the increase in prescription drug expenditure
wasn't price, but volume, then, the effect of policies fo-
cusing on price-cuts and unaccompanied by demand-
side initiatives would remain limited and stay short-term
in nature. Therefore, in order to approach the issue of
constraining prescription drug expenditure increases, we
need first to examine the various factors surrounding
the phenomenon, including price, volume, and prescrip-
tion changes, and their influence on prescription drug
expenditure increases [5,6].
When we examine the influences the three above-
mentioned factors have on changes in prescription drug
expenditures, we find that their influence varies according
to the drug. This study examines the influence lipid-
lowering drugs have on the prescription drug expend-
iture increase. The lipid-lowering drug expenditure
increased sharply, doubling from 2005 to 2009 [7]. This
drug was also influenced the most by various policy
changes during this period. As the patent expired in
August 2008, the price of the original atorvastatin
lowered by 20%. In particular, as a result of re-evaluating
the listed drugs, which indicated that there were no
significant differences among statins in their effects on
lowering LDL, the prices of all statins above a certain price
were lowered two times by 5% ~ 37.5% (an average 10.3%)
in April 2009 and in January 2010 [4]. Despite thesechanges, lipid-lowering drug expenditures continued to
grow steadily [7]. It is necessary for us first to look
into various factors influencing the lipid-lowering
drug expenditure increase in detail. Results of the
current study could offer useful suggestions for future




For our study we used the Korean National Health
Insurance Claims Database (KNHICD). The Korean
National Health Insurance plan provides coverage for 97%
of the entire South Korean population. NHI benefits not
only cover outpatient, inpatient and emergency care, but
also prescription drugs dispensed at pharmacies. We fo-
cused on lipid-lowering drugs that were prescribed and
dispensed in outpatient settings between 2005 and 2009.
We defined lipid-lowering drugs in this study as drugs
with an Anatomical-Therapeutic Classification System
(ATC) code that corresponded to ‘C10 LIPID MODIFY-
ING AGENTS’. Given that statins represent more than
90% of all pharmaceutical expenditures for lipid-
lowering drugs, we decided to focus on statins alone as
our final study target. We estimated the price of an indi-
vidual drug using an annual weighted average price cal-
culated as the annual expenditure divided by annual
consumption. The amount of statin consumed was com-
puted based on the Defined Daily Dose of the World
Health Organization (WHO-DDD) at 2010 [8-10]. With
the sole unit of DDD, it was feasible to compare the
amount of drug consumed among identical active ingre-
dients even when they had different strength and admin-
istration routes.
The current study was approved of by the Institutional
Review Board (IRB) of Health Insurance Review and As-
sessment Services (HIRA).
Method
We calculated the yearly variation of statin expenditures
by measuring the increased rate of paired pharmaceutical
expenditures for a 2 year period. We added "Expenditure"
only to the price of the drugs and did not include com-
pounding fees, etc. In Korea, patient co-payment is a cer-
tain percentage of total expenditures that compose drug
prices plus compounding fees. Thus, "expenditures" in this
study were defined as total drug cost including some of
the patient co-payment. We adjusted for inflation by div-
iding the monetary time series by the Consumer Price
Index (CPI) with the CPI being scaled so that 2009 value
was 1.0 [11]. And we used exchange rate listed by the
Bank of Korea (Additional file 1) [12]. Referring to the
study of Chernew (2001), we categorized statins as new
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Figure 1 Framework of the statin expenditure analysis.
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used during the previous year but were used in the base
year. Core medicines were drugs that were used during
both years. Exiting medicines were defined as drugs that
were used during the previous year but were not used in
the base year. We further divided new entrants into new
molecular entities, new medicines, new generic medicines,
and others. New molecular entities referred to compounds
that the NHI covered during the specified year. We de-
fined new medicines as drugs recently listed with new ad-
ministration routes or chemical compositions but with
their active ingredients already included in the NHI bene-
fit list for the specified year. New generic medicines were
primarily identified as newly launched generic drugs for
which the original patent had expired. The rest of the
drugs within the new entrants were classified as "others".
These medications were already listed in NHI benefit list
but were not used during the comparable period.
The number of active ingredients in our study was 19
(183 drugs) in 2005 but this was expanded to 30 active
ingredients (271 drugs) in 2009 (Table 1).
Table 2 divided statins on the KNHI (Korea National
Health Insurance) benefit list into 7 different types ac-
cording to their ingredients, additionally subdividing
them into original and generic drugs. These included all
statins on the KNHI benefit list between 2005 and 2009,
regardless of whether they were actually prescribed or
not. This table indicates that many atorvastatin generic
drugs were placed on the benefit list at around same
time in July 2008 when the patent expired.
We computed the yearly variation of statin expenditures
starting in 2005 by calculating the increased rate of paired
pharmaceutical expenditures observed over a two-year
period. One can express spending increases for statinsbetween the previous year (0) and base year (1) with the
following equation when the targeted drugs were classified
as new entrants, core medicines, and existing medicines:
S1
S0










: Total drug expenditures for the base year (1) and
previous year (0)
C1,C0: Core medicines expenditures for the base year
(1) and previous year (0)
N1: New entrants expenditures for the base year (1)














: Increased rate for new entrants
We further divided expenditures for core medicines by
the price of medication, amount of drugs consumed by
volume, and prescription changes, which we have illus-
trated in the equation slightly further below. There are
two possible factors that could have led to prescription
changes: Generic Mix or Ingredient Mix. Generic Mix
refers to cases where prescribed drugs were substituted
for other medicines with identical generic names. Since
the two drugs shared the same generic name, their in-
gredients, dosage type and action mechanisms were
identical even as their prices differed. We determined
whether pharmaceutical expenditures for 2 years showed
Table 1 Number of drugs and active ingredients among statins*
Year 2005 2006 2007 2008 2009
Number of drugs Total 183 207 217 227 271
Core medicines (A) 167 192 176 204
Exiting medicines (B) 16 15 41 23
New entrants (C) 40 25 51 67
- New molecular entities 0 0 0 1
- New medicines 1 0 1 5
- New generic medicines 9 13 37 29
- Others 30 12 13 32
Number of active ingredients Total 19 22 23 24 30
Core medicines (A) 19 22 23 24
Exiting medicines (B) 6 4 8 6
New entrants (C) 13 8 12 17
- New molecular entities 0 0 0 1
- New medicines 1 0 1 5
- New generic medicines 6 5 6 5
- Others 6 3 5 6
*This table includes only those statins that were prescribed by doctors out of statins on the Korean National Health Insurance benefit list.
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with the same ingredients. Ingredient Mix refers to the
cases in which the existing drugs were replaced with
other drugs in the same therapeutic category. For ex-
ample, if a patient changed his or her drug from simva-
statin to atorvastatin, one could express this as an
Ingredient Mix since both medications belonged to the
statin classification.
Core medicine expenditure Cð Þ
¼ Σðindividual drug price generic mix
 Ingredient mix total volumeÞTable 2 Number of statins on KNHI benefit list (2005–2009 ye
Year 2005 2006
Statins Original Generic** Original Generic*
Simvastatin (10, 20, 40, 80 mg) 3 125 3 134
Lovastatin (20 mg) 1 54 1 56
Pravastatin (5,10,20,40 mg) 0 49 0 50
Fluvastatin (20,40,80 mg) 3 0 3 0
Atorvastatin (10,20,40,80 mg) 3 0 3 0
Rosuvastatin (5,10,20 mg) 2 0 3 0
Pitavastatin (2 mg) 1 0 1 0
Total 241 254
*They include all statins on the KNHI benefit list between 2005 and 2009, regardles
**The original and generic drugs were categorized only according to their ingredien





































Original Generic** Original Generic** Original Generic**
3 135 3 118 4 100
1 52 1 35 1 25
0 81 0 56 0 48
3 0 3 0 3 0
3 0 4 42 4 54
3 0 3 0 3 0
1 0 1 0 1 0
282 266 243
f whether they were actually prescribed or not.


















qij: total dose of all drugs.
Results
Our study demonstrated that statins accounted for 90%
of total lipid-lowering drug expenditures. Annual expen-
ditures for statins increased from 193 million won (188
million USD) in 2005 to 483 million won (378 million
USD) in 2009 (an annual average of 25.7% during the
study period). The annual statin DDD also showed an
increase of 36.4% (from 129 million DDD in 2005 to 445
million DDD in 2009) while statin expenditure per DDD
decreased 7.9% (1,506 won (1.47 USD) in 2005 to 1,085
won (0.85 USD) in 2009) (Table 3). As the patent expired
in August 2008, the price of the original atorvastatin
lowered by 20%. Also, as a result of re-evaluating the listed
drugs, its insurance price lowered by an average of
11% in April 2009. Such a price reduction influenced the
continuous decreasing of statin expenditure per DDD.
For a detailed analysis, we calculated drug expenditure
percentages according to seven different statins. Our re-
sult showed that the percentage of simvastatin was the
highest (41.9%) in 2005, followed by atorvastatin (31.2%)
and pravastatin (9.2%). However, during the 4 year study
period, simvastatin and lovastatin declined to 24.9% and
0.9% respectively. On the other hand, the percentage of
atorvastatin increased rapidly to 49.0%, and the percent-
age of rosuvastatin rose to 11.8%. Atorvastatin particu-
larly showed a rapid increase after 2008 when the
original patent expired and generic drugs began to ap-
pear on the market. Pitavastatin use fluctuated slightly,
increasing from 3.8% in 2006 to 7.6% in 2008, but de-
creasing to 6.4% in 2009 (Figure 2) (Additional file 2).
We also compared the amount of the seven statins con-
sumed throughout this study. In 2005, simvastatin occu-
pied 47.8% of the total statin DDD (Defined Daily Dose)ble 3 Changes in annual DDD and drug expenditures (year
2005 2006 2007
atin Sum of DDD 128,545,620 193,278,414 (50.36%) 274,288,69
Drug expenditure














208.9 288.5 (38.09%) 378.7 (31.2
he drug expenditure was adjusted for inflation.followed by atorvastatin (20.6%), pravastatin (9.9%), lova-
statin (9.0%), and rosuvastatin (8.4%). Our analysis dem-
onstrated that there was significant fluctuation among the
DDD proportion of the seven statins during the 4 year
study period. The atorvastatin share, which ranked second
in 2005, increased dramatically to 47.6% of the entire sta-
tin DDD in 2009. The percentage for simvastatin, on the
other hand, plummeted to 24.5%. Use of rosuvastatin
showed a slight increase (DDD proportion of 12.4%). In
contrast, the DDD proportion of pravastatin decreased to
4.6% while lovastatin dropped to 0.9% (Figure 3).
Lastly, we explored the significant factors that influ-
enced drug expenditure changes during the study period.
We found that core medicines contributed the most to
statin expenditure increases. Exiting medicines led the
expenditure decrease of 13.4% in 2006 but had no sig-
nificant influence thereafter. New entrants positively af-
fected statin expenditure between 2006 and 2008 (from
2.7% to 10.5%) but rarely affected it in 2009 (1.0%).
Drug prices, which showed a continuous decrease,
seemed to reduce the expenditures for statin. Especially,
price factor contributed the most statin expenditure de-
creases, because insurance price of statins lowered by an
average of 11.0% in 2009. However consumption volume
increased annually and contributed to a substantial in-
crease in statin expenditures. Since the patent for ator-
vastatin expired in 2008 and use of generic drugs
increased, Generic Mix drove a statin expenditure de-
crease while the Ingredient Mix effect led to an expend-
iture increase of 5.3% (assuming the average rate of
increase was 100%). This resulted from an increased use
of more expensive active ingredients within the statin
(Table 4).
Discussion
Recently, hyperlipidemia has been on the rise in South
Korea. Between 2005 and 2010, the prevalence of hyper-
lipidemia among people over 30 increased from 8.0% to
13.5%, while the prevalence of hypertension and diabetes
rose from 24.6% to 26.9% and from 9.1% to 9.7% re-
spectively [13]. Additionally, drug expenditures for lipid--to-year rates of increase in parenthesis)
2008 2009 2005-2009 Annual
9 (41.91%) 344,893,058 (25.74%) 445,426,185 246.51% 36.44%
1,185 1,085 −27.95% −7.87%
2%) 408.8 (16.82%) 483.1 (18.16%) 149.57% 25.69%
9 (39.90%) 392,818,319 (25.06%) 506,311,055 (28.89%) 227.01% 34.47%
1,136 1,052 −22.02% −6.03%

































Figure 2 Expenditure trends for the seven different statins.
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over, compared to 2009, the use of lipid-lowering drugs
in South Korea increased 27.4% in 2011 [7].
As is well known, hyperlipidemia is a major risk factor
in contracting cardiovascular diseases. Hobbs (2004) re-
ported that there is a more than 30% chance of cardio-
vascular disease development when cholesterol levels
increase by 10%. If cholesterol levels increase by 30%,
the risk of cardiovascular disease doubles [14]. In order
to properly control hyperlipidemia, various recommen-
dations have been made that include receiving lipid-
lowering drugs along with maintaining a healthy diet
and getting ample exercise [14-19].
Considering the notable effects of cardiovascular disease
prevention, hyperlipidemia patients should take lipid-
lowering drugs when necessary. In situations where the
number of hyperlipidemia patients are rapidly increasing,
the resulting increase in lipid-lowering drug prescriptions







Figure 3 DDD proportion changes for each statin.This study was designed to find a more effective way to
constrain lipid-lowering prescription drug expenditures by
examining the various primary factors influencing in-
creases in expenditures.
By focusing on statins, which accounted for 90% of both
lipid-lowering drug expenditures and consumption volume,
we sought to identify the factors that drove expenditure in-
creases. For our detailed analyses, we examined price, the
amount of drugs consumed (volume), and prescription
changes (substitutes for other drugs). For the amount of
drugs consumed, we applied the DDD in order to standar-
dize the volume of drugs with identical active ingredients re-
gardless of their different administration routes, dosage
forms, or strength and unit. Our current study's findings im-
plied that increased expenditure for lipid-lowering drugs in
South Korea was driven mainly by core medicines. Further
analyses revealed that drug price consistently lowered statin
expenditures while Generic Mix (the relative gap between








Table 4 Effect of different factors on statin expenditure changes*
2005 2006 2007 2008 2009 Average
Year-on-year increased statin expenditure rate (%)* (T) 35.92 26.90 11.60 14.99 21.97
Core medicines (year-to-year rates of increase: %, A) 46.62 23.61 2.32 14.17 18.24
- Price (△P) −7.18 −0.33 −0.22 −6.21 −2.98
-Within-component mix (generic mix) 5.36 −2.12 −1.77 −2.06 −0.90
-Between-component mix 4.54 0.83 0.10 1.19 1.36
(Ingredient mix)
- Volume (△Q) 47.94 32.21 5.04 21.58 23.48
New entrants (year-to-year rates of increase: %, B) 2.69 3.30 10.54 0.96 6.43
- New molecular entities 0.00 0.00 0.00 0.00 0.00
- New medicines 0.00 0.00 0.01 0.34 0.12
- New generic medicines 1.87 3.23 10.53 0.30 5.13
- Others 0.82 0.07 0.00 0.32 0.26
Exiting medicines (year-to-year rates of increase: %, C) −13.39 0.00 −1.26 −0.14 −2.70
*The drug expenditure was adjusted for inflation.
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use of generic drugs and could explain why most of the
new entrants were considered ‘new products (generic).’
Additionally, prescription changes raised statin expendi-
tures slightly due to an increased use of relatively expen-
sive ingredients (Ingredient Mix effect). The results of this
study also demonstrated that volume increases drove sta-
tin expenditures increases. Previous investigations analyz-
ing South Korean drug expenditures from 2001 to 2006
also reported that volume increased due to an increasing
number of patients, with prescriptions and prescribed days
also acting as a main contributor [20-22]. Characteristic-
ally, after 2008, when the atorvastatin patent expired and
various generic drugs began to appear on the market, ator-
vastatin expenditures increased significantly. This appears
to be due to the fact that the production of generic drugs
opened the possibility for doctors to prescribe a wider var-
iety of lipid-lowering drugs. This conclusion is consistent
with findings from a previous study by Kwon (2013),
which found that the release of generic drugs on the mar-
ket tended to not only replace the original drug market,
but to also increase the overall market share for medica-
tion composed of essentially the same ingredients [4].
As mentioned in our introduction, the price of lipid-
lowering drugs decreased during two significant periods
between 2005 and 2009. Nevertheless, overall lipid-lowering
drug expenditures continued to increase during 2008 and
2009. This was due to increases in the number of patients
using these drugs and the number of their adminis-
tration dates, as is shown in the increase in the entire
DDD. In other words, the increase in lipid-lowering drug
consumption was the main factor for expenditure
increases. Therefore, it is clear that supply-side initiatives
focusing on lowering prices would not be enough to
effectively constrain drug expenditure increases.Godman [23] argues that taking only one between
supply-side initiative and demand-side initiative results
in a limited effect on the constraint of prescription drug
increases. Furthermore, one can maximize prescribing
efficiency only when combining the two initiatives. He
also argues that combining various demand-side initia-
tives amplifies the effect. In fact, the kind of increase in
statin utilization witnessed in Korea is similar to statin
utilization trends across Europe [23]. However, while
statin use increased in the U.K. and Sweden, accom-
panying expenditures did not increase proportionally.
One can impute these efficient expenditure numbers to
their use of combined demand-side measures such as
target prescription, compulsory INN prescription, posi-
tive and negative financial incentives, and mandatory
generic substitutions. In Germany as well, in order to
constrain the prescription drug expenditure and encour-
age generic drug prescription, authorities introduced tar-
get prescription as a cost-saving measure. This system
was accompanied by offering immediate feedback so that
doctors could monitor their own performance. It was
through this combination of target prescription accom-
panied by educational methods and introducing a price-
reference system that Germany was able to activate a
relatively cheaper generic drug market [24,25]. In Korea,
where the number of individuals with chronic illnesses
have continued to rise, the authorities have made efforts
to develop demand-side initiatives in addition to supply-
side initiatives like lowering prices in order to effectively
constrain prescription drug expenditure increases. For
example, there is the prescribing incentive scheme (IPS),
a system in which doctors are offered 30% of the saved
drug cost if they voluntarily improve their prescription
behavior and save drug costs. Also, in April 2012, Korea
introduced a new price system where the highest price
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of the original drug price, twelve months after the date
the generic drug was listed and at the same time as the
original drug’s patent expired. Because of this, the differ-
ence between the prices of original and generic drugs
disappeared as well as the difference in co-payments.
One could expect that the generic drug market could
shrink slightly if one were to introduce this system.
These initiatives clearly had some significant effect on
limiting the prescription drug expenditures. Neverthe-
less, it would still be preferable to introduce more di-
verse demand-side initiatives to continue checking
prescription drug expenditure increases and to maximize
prescription efficiency.
The present study had several limitations. First, it was
difficult to accurately measure drug usage volume. We
confined our study to medications used for hyperlipid-
emia and measured consumption volume by adopting
the DDD. However, drug consumption data presented in
DDDs only gave a rough estimate of consumption and
not an exact picture of actual use [26]. Second, the study
method we used was not sufficient for assessing the im-
pact of introducing new drugs on changes in drug ex-
penditures [27]. Every year, pharmaceutical companies
launch newly developed drugs and products while re-
moving many existing drugs from the market. For this
reason, studies are usually conducted either every year
or once every 3 years, a short period for new entrants to
acquire a certain level of the market share. Therefore,
one might underestimate the influence of new entrants
on current drug expenditures with those of the previous
year. However, statins had few “new molecular entities”
among “new drugs,” and most of the new drugs in our
study sample were generic and had already acquired ex-
pired patents. Therefore, this common limitation that
could have led to us underestimating our results would
not have impacted our analysis.Conclusions
As chronic diseases including hyperlipidemia increase
steadily in South Korea, it is necessary to introduce not
only supply-side measures but also various demand-side
measures such as educational courses for rational pre-
scription, programs promoting cost-effective prescription
drug usage, and a prescription target system to effectively
constrain prescription drug expenditure increases.Additional files
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